-$0.14 Earnings Per Share Expected for OncoSec Medical Inc (ONCS) This Quarter

Equities analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to announce ($0.14) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.18) in the same quarter last year, which indicates a positive year over year growth rate of 22.2%. The business is scheduled to announce its next quarterly earnings results on Wednesday, June 12th.

According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next fiscal year, analysts expect that the company will report earnings of ($0.65) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover OncoSec Medical.

A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of OncoSec Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research note on Monday, April 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $3.13.

Shares of NASDAQ ONCS traded up $0.03 during trading on Friday, reaching $0.50. The company had a trading volume of 127,735 shares, compared to its average volume of 317,930. OncoSec Medical has a 52 week low of $0.42 and a 52 week high of $1.96.

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its position in OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after acquiring an additional 240,843 shares during the last quarter. Bank of New York Mellon Corp grew its position in OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 83,150 shares during the period. Moloney Securities Asset Management LLC grew its position in OncoSec Medical by 117.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 27,000 shares during the period. Northern Trust Corp grew its position in OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 28,914 shares during the period. Finally, Geode Capital Management LLC grew its position in OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 163,405 shares during the period. 6.39% of the stock is owned by institutional investors and hedge funds.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Recommended Story: Moving Average (MA)

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.